<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-06-08T01:05:46Z</responseDate><request verb="GetRecord" identifier="oai:docta.ucm.es:20.500.14352/115839" metadataPrefix="mods">https://docta.ucm.es/rest/oai/request</request><GetRecord><record><header><identifier>oai:docta.ucm.es:20.500.14352/115839</identifier><datestamp>2025-01-24T00:48:01Z</datestamp><setSpec>com_20.500.14352_14</setSpec><setSpec>col_20.500.14352_15</setSpec></header><metadata><mods:mods xmlns:mods="http://www.loc.gov/mods/v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
   <mods:name>
      <mods:namePart>Martínez Martínez, Ernesto</mods:namePart>
   </mods:name>
   <mods:name>
      <mods:namePart>Calvier L,</mods:namePart>
   </mods:name>
   <mods:name>
      <mods:namePart>Fernández-Celis A,</mods:namePart>
   </mods:name>
   <mods:name>
      <mods:namePart>Rousseau E</mods:namePart>
   </mods:name>
   <mods:name>
      <mods:namePart>Jurado-López R</mods:namePart>
   </mods:name>
   <mods:name>
      <mods:namePart>Rossoni LV</mods:namePart>
   </mods:name>
   <mods:name>
      <mods:namePart>Jaisser F</mods:namePart>
   </mods:name>
   <mods:name>
      <mods:namePart>Zannad F</mods:namePart>
   </mods:name>
   <mods:name>
      <mods:namePart>Rossignol P,</mods:namePart>
   </mods:name>
   <mods:name>
      <mods:namePart>Cachofeiro Ramos, María Victoria</mods:namePart>
   </mods:name>
   <mods:name>
      <mods:namePart>López-Andrés N</mods:namePart>
   </mods:name>
   <mods:extension>
      <mods:dateAvailable encoding="iso8601">2025-01-23T12:37:56Z</mods:dateAvailable>
   </mods:extension>
   <mods:extension>
      <mods:dateAccessioned encoding="iso8601">2025-01-23T12:37:56Z</mods:dateAccessioned>
   </mods:extension>
   <mods:originInfo>
      <mods:dateIssued encoding="iso8601">2015-10-01</mods:dateIssued>
   </mods:originInfo>
   <mods:identifier type="citation">Martínez-Martínez E, Calvier L, Fernández-Celis A, Rousseau E, Jurado-López R, Rossoni LV, Jaisser F, Zannad F, Rossignol P, Cachofeiro V, López-Andrés N. Galectin-3 blockade inhibits cardiac inflammation and fibrosis in experimental hyperaldosteronism and hypertension. Hypertension. 2015 Oct;66(4):767-75. doi: 10.1161/HYPERTENSIONAHA.115.05876. Epub 2015 Aug 3. PMID: 26238446.</mods:identifier>
   <mods:identifier type="doi">10.1161/HYPERTENSIONAHA.115.05876</mods:identifier>
   <mods:identifier type="uri">https://hdl.handle.net/20.500.14352/115839</mods:identifier>
   <mods:identifier type="essn">0194-911X</mods:identifier>
   <mods:identifier type="officialurl">https://doi.org/10.1161/HYPERTENSIONAHA.115.05876</mods:identifier>
   <mods:identifier type="pmid">26238446</mods:identifier>
   <mods:identifier type="relatedurl">https://pubmed.ncbi.nlm.nih.gov/26238446/</mods:identifier>
   <mods:identifier type="relatedurl">https://www.ahajournals.org/doi/10.1161/hypertensionaha.115.05876</mods:identifier>
   <mods:abstract>Hypertensive cardiac remodeling is accompanied by molecular inflammation and fibrosis, 2 mechanisms that finally affect cardiac function. At cardiac level, aldosterone promotes inflammation and fibrosis, although the precise mechanisms are still unclear. Galectin-3 (Gal-3), a β-galactoside-binding lectin, is associated with inflammation and fibrosis in the cardiovascular system. We herein investigated whether Gal-3 inhibition could block aldosterone-induced cardiac inflammation and fibrosis and its potential role in cardiac damage associated with hypertension. Aldosterone-salt-treated rats presented hypertension, cardiac inflammation, and fibrosis that were prevented by the pharmacological inhibition of Gal-3 with modified citrus pectin. Cardiac inflammation and fibrosis presented in spontaneously hypertensive rats were prevented by modified citrus pectin treatment, whereas Gal-3 blockade did not modify blood pressure levels. In the absence of blood pressure modifications, Gal-3 knockout mice were resistant to aldosterone-induced cardiac inflammation. In human cardiac fibroblasts, aldosterone increased Gal-3 expression via its mineralocorticoid receptor. Gal-3 and aldosterone enhanced proinflammatory and profibrotic markers, as well as metalloproteinase activities in human cardiac fibroblasts, effects that were not observed in Gal-3-silenced cells treated with aldosterone. In experimental hyperaldosteronism, the increase in Gal-3 expression was associated with cardiac inflammation and fibrosis, alterations that were prevented by Gal-3 blockade independently of blood pressure levels. These data suggest that Gal-3 could be a new molecular mechanism linking cardiac inflammation and fibrosis in situations with high-aldosterone levels, such as hypertension.</mods:abstract>
   <mods:language>
      <mods:languageTerm>eng</mods:languageTerm>
   </mods:language>
   <mods:accessCondition type="useAndReproduction">restricted access</mods:accessCondition>
   <mods:titleInfo>
      <mods:title>Galectin-3 blockade inhibits cardiac inflammation and fibrosis in experimental hyperaldosteronism and hypertension. Hypertension</mods:title>
   </mods:titleInfo>
   <mods:genre>journal article</mods:genre>
</mods:mods></metadata></record></GetRecord></OAI-PMH>